The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,588.00
Ask: 12,590.00
Change: -34.00 (-0.27%)
Spread: 2.00 (0.016%)
Open: 12,626.00
High: 12,646.00
Low: 12,474.00
Prev. Close: 12,590.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Thu, 11th Apr 2024 17:07

Outlook hike sends Ambu shares up

*

AstraZeneca rises on plans to hike annual dividend

*

Lufthansa extends suspension of flights to Tehran

*

STOXX 600 off 0.4%

April 11 (Reuters) - Europe's benchmark stock index fell to a one-month low on Thursday, as banks took a hit after the European Central Bank held rates steady but signalled imminent cuts, while Deutsche Telekom dropped to a five-month low on trading ex-dividend.

The ECB maintained interest rates at record high as expected, but signalled it may soon start to cut them, even as investors question whether stubborn U.S. inflation will stop the Federal Reserve from following close behind.

The pan-European STOXX 600 closed 0.4% lower in volatile trade, with the banking sector taking the biggest hit, falling 2.4% and notching its steepest one-day drop in over eight months.

The indexes of top economies in the currency union such as Germany, France, Italy and Spain were also down between 0.3% to 1.2%.

"The ECB's decision to update its guidance suggests that an interest rate cut at the next meeting in June is very likely," Jack Allen-Reynolds, deputy chief euro zone economist at Capital Economics wrote.

"We expect the Bank to reduce the deposit rate from 4% currently to 3% by the end of the year."

The telecoms sector also shed 2.1%, dragged down by a 6.2% drop in Deutsche Telekom as the company traded ex-dividend.

Also denting equities were higher euro zone bond yields as expectations for a higher-for-longer scenario for U.S. interest rates more than offset the ECB remarks.

Investors also parsed a cooler-than-expected March producer inflation data in the United States.

After a lacklustre week, the STOXX 600 had hit a one-month low on Wednesday after a hot U.S. inflation report sparked concerns on the timeline for the Federal Reserve's first rate cut, while raising expectations that the ECB could lower rates before its U.S. counterpart.

Among other sectors, utilities and healthcare were among the rare bright spots, up 0.5% each.

As for individual stocks, Ambu climbed 4.6% after the Danish maker of single-use endoscopy solutions hiked its full-year outlook and posted preliminary second-quarter financials.

Lufthansa dropped 2.7% after the German carrier extended a suspension of its flights to Tehran, with the Middle East on alert for Iranian retaliation for a suspected Israeli airstrike on the country's embassy in Syria.

Idorsia postponed its 2023 and first-quarter results publication, sending the Swiss biotech firm's shares down 26.4%.

AstraZeneca rose 2.1% after the drugmaker said it planned to increase its annual dividend by 7% for 2024. (Reporting by Johann M Cherian, Ozan Ergenay and Ankika Biswas; Editing by Shounak Dasgupta, Arun Koyyur and Alison Williams)

More News
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.